StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$149.52+3.19 (+2.18%)

Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%

Merck Total Vaccines Franchise — Worldwide sales by Quarter

Total Vaccines Franchise — Worldwide sales ($M) ($M)

QuarterlyAnnual

Merck Total Vaccines Franchise — Worldwide sales: $0M in Q2 2026, down 100.0% from a year earlier. That is the lowest of the 18 quarters on record here.

Latest, Q2 2026
0
Period ended Jun 30, 2026
Change on a year earlier
-100.0%
5 in Q2 2025
History
18 quarters
Since Q1 2022
Sources
4
Documents cited below

Where the Q2 2026 figure comes from

“$132 million and $0 million in the first and second quarter of 2026”

Source: Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗

Reported in Form 8-K Supplemental Table 3 Footnote (Total Vaccines sales).

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedTotal Vaccines Franchise — Worldwide sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 20260-100.0%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q1 2026Mar 31, 2026132+38.9%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q4 2025Dec 31, 2025579+6.0%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q3 2025Sep 30, 2025703+18.8%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q2 2025Jun 30, 20255-99.3%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q1 2025Mar 31, 202595-87.2%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q4 2024Dec 31, 2024546-81.6%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q3 2024Sep 30, 2024592-85.2%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q2 2024Jun 30, 2024715-79.9%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q1 2024Mar 31, 2024745-76.2%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q4 2023Dec 31, 20232,962+16.0%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q3 2023Sep 30, 20234,002+12.7%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q2 2023Jun 30, 20233,557+31.3%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q1 2023Mar 31, 20233,133+26.3%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q4 2022Dec 31, 20222,554–Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
Q3 2022Sep 30, 20223,552–Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗

Cite this data

StockData. (2026). Merck Total Vaccines Franchise — Worldwide sales ($M), quarterly Q1 2022–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-total-vaccines

See every metric in the Merck KPI table. Data updated Oct 26, 2026.